Immunic IMUX
NASDAQ IMUX
$8.91 -0.60 (-6.31%)
At close: Sep 29, 2026 · 4:00 PM EDT

Immunic (IMUX) Restructuring Costs (2018 - 2019)

Updated

Immunic's Restructuring Costs came in at $6.37 million for Q1 2019.

Analysis

Immunic (IMUX) Restructuring Costs (2018 - 2019) Analysis & Trends

Over the trailing twelve months to Mar 31, 2019, Immunic reported Restructuring Costs of $8.76 million; for FY2018, it was $2.4 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Immunic 404.31 Mn 404.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 6.37 Mn
Sep 30, 2018 2.40 Mn
API Access

Immunic Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=IMUX&period=max&api_key=YOUR_API_KEY